Company intelligence / Profile preview

Renkangya

Shenzhen, Guangdong, China

Ownership: Private
Development stage: Other

Overview

Renkangya (Shenzhen) Biomedical Technology Co., Ltd. (formerly Guangzhou Renkangya Biomedical Technology Co., Ltd.) is a clinical-stage Chinese biotechnology company focused on developing novel peptide therapeutics for cardiovascular diseases. The company's lead candidate is GNP (G-type natriuretic peptide), a 38-amino-acid cyclic peptide originally derived from the venom of the East African green mamba (Dendroaspis angusticeps). GNP acts as a natriuretic peptide receptor 1 (NPR1/NPRA) agonist and is currently in Phase II clinical development for the treatment of acute decompensated heart failure and pulmonary arterial hypertension. Renkangya is backed by prominent Chinese investors, including the family office of Gong Hongjia and Chen Chunmei.

Therapeutic areas: Cardiovascular
Modalities: PeptideBiologic
Industry: Biotech

Drug pipeline

1 asset

GNP

Unknown

Beyond the preview

Go deeper on Renkangya.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Renkangya.